Regeneron Announces Investor Conference Presentations

Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) has announced its participation in two major healthcare investor conferences in March 2025. The company will present at the TD Cowen 45th Annual Health Care Conference on March 4 at 11:50 a.m. ET, and the Leerink Partners 2025 Global Healthcare Conference on March 11 at 8:00 a.m. ET.

Both presentations will be accessible via webcast through Regeneron's investor relations website. The company will maintain archives of the webcasts and transcripts for a minimum of 30 days on their corporate website's 'Investors & Media' section.

News Market Reaction

-0.24%

1 alert

-0.24% News Effect

On the day this news was published, REGN declined 0.24%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

• TD Cowen 45^th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025
• Leerink Partners 2025 Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 11, 2025

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com        

FAQ

When is Regeneron (REGN) presenting at the TD Cowen Healthcare Conference in 2025?

Regeneron (REGN) is presenting at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET.

What time is Regeneron's (REGN) presentation at the Leerink Partners Conference in March 2025?

Regeneron (REGN) will present at the Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025, at 8:00 a.m. ET.

How long will Regeneron's (REGN) March 2025 conference webcasts be available for replay?

Regeneron will archive the webcasts and transcripts on their corporate website for at least 30 days.

Where can investors access Regeneron's (REGN) March 2025 conference presentations?

Investors can access the conference webcasts through Regeneron's website at investor.regeneron.com in the 'Investors & Media' section under events and presentations.